{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:51:20Z","timestamp":1744365080373},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NHGRI","award":["U01 HG 007269","U01HG006380"],"award-info":[{"award-number":["U01 HG 007269","U01HG006380"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","interventional.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.iccl.2016.08.010","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T07:00:46Z","timestamp":1479884446000},"page":"141-149","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genetic Determinants of P2Y12 Inhibitors and Clinical Implications"],"prefix":"10.1016","volume":"6","author":[{"given":"Larisa H.","family":"Cavallari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniwaa Owusu","family":"Obeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iccl.2016.08.010_bib1","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2016.08.010_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.010_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cts.12383","article-title":"Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population","volume":"9","author":"Khalil","year":"2016","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.iccl.2016.08.010_bib4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.amjcard.2011.06.060","article-title":"Comparison of platelet reactivity and clopidogrel response in patients <\/= 75 Years Versus\u00a0> 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome","volume":"108","author":"Cuisset","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib5","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.010_bib7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.010_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4330\/wjc.v8.i5.327","article-title":"P2Y12-ADP receptor antagonists: days of future and past","volume":"8","author":"Laine","year":"2016","journal-title":"World J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.iccl.2016.08.010_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-013-0105-2","article-title":"Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases","volume":"53","author":"Karazniewicz-Lada","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.iccl.2016.08.010_bib11","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.010_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2796.2002.01027.x","article-title":"Individual variations of platelet inhibition after loading doses of clopidogrel","volume":"252","author":"Jaremo","year":"2002","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.iccl.2016.08.010_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.010_bib14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","article-title":"Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib15","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.010_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","article-title":"Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel","volume":"128","author":"Roe","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.010_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.010_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2011.96","article-title":"The evolution of antiplatelet therapy in cardiovascular disease","volume":"8","author":"Yousuf","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2013.757303","article-title":"Ticagrelor: the first novel reversible P2Y(12) inhibitor","volume":"14","author":"Htun","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.iccl.2016.08.010_bib21","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib22","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.010_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2016.08.010_bib24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2016.08.010_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.010_bib26","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.iccl.2016.08.010_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","article-title":"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19","volume":"22","author":"Scott","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.iccl.2016.08.010_bib28","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(12)61398-1","article-title":"Pharmacogenetic guidance for antiplatelet treatment","volume":"380","author":"Jeong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.010_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.iccl.2016.08.010_bib30","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1538-7836.2010.03921.x","article-title":"Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy","volume":"8","author":"Sibbing","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.010_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2016.08.010_bib32","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.010_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.010_bib34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jcin.2014.04.020","article-title":"Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study","volume":"7","author":"Palmerini","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.010_bib35","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2016.08.010_bib36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jacc.2015.12.036","article-title":"Impact of CYP2C19 metabolizer status on patients with ACS treated with prasugrel versus clopidogrel","volume":"67","author":"Doll","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.010_bib37","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2016.08.010_bib38","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","article-title":"CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis","volume":"7","author":"Sorich","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.iccl.2016.08.010_bib39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.010_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","article-title":"The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response","volume":"23","author":"Lewis","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.iccl.2016.08.010_bib41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.010_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/FPC.0b013e328333dafe","article-title":"Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation","volume":"20","author":"Harmsze","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.iccl.2016.08.010_bib43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.72.1165","article-title":"Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel","volume":"72","author":"Malek","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.iccl.2016.08.010_bib44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jcph.293","article-title":"Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers","volume":"54","author":"Horenstein","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.iccl.2016.08.010_bib45","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2016.08.010_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1160\/TH15-12-0981","article-title":"Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights form the ELEVATE-TIMIT 56 Trial","volume":"116","author":"Carreras","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.010_bib47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","article-title":"Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450","volume":"34","author":"Rehmel","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.iccl.2016.08.010_bib48","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.010_bib49","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/j.1538-7836.2010.03923.x","article-title":"Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data","volume":"8","author":"Sorich","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.010_bib50","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIR.0b013e3181ee08ed","article-title":"ACCF\/AHA Clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association","volume":"122","author":"Society for Cardiovascular Angiography and Interventions","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.010_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cpt.331","article-title":"Physician response to implementation of genotype-tailored antiplatelet therapy","volume":"100","author":"Peterson","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.iccl.2016.08.010_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajmg.c.31396","article-title":"Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program","volume":"166C","author":"Shuldiner","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.iccl.2016.08.010_bib53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajmg.c.31390","article-title":"Clinical pharmacogenetics implementation: approaches, successes, and challenges","volume":"166C","author":"Weitzel","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.iccl.2016.08.010_bib54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/pgs.14.180","article-title":"Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients","volume":"16","author":"Lee","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.iccl.2016.08.010_bib55","doi-asserted-by":"crossref","first-page":"A11802","DOI":"10.1161\/circ.132.suppl_3.11802","article-title":"Clinical implementation of CYP2C19 genotype guided antiplatelet therapy reduces cardiovascular events after PCI","volume":"132","author":"Cavallari","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.010_bib56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1160\/TH13-01-0021","article-title":"Cytochrome P450 2B6 and 2C9 genotype polymorphism\u2013a possible cause of prasugrel low responsiveness","volume":"110","author":"Franken","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.010_bib57","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","article-title":"Effect of genetic variations on ticagrelor plasma levels and clinical outcomes","volume":"36","author":"Varenhorst","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816300931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816300931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T16:06:01Z","timestamp":1657814761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745816300931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S2211745816300931"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.010","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Determinants of P2Y12 Inhibitors and Clinical Implications","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}